Literature DB >> 15712334

The interaction of highly helical structural mutants with the NOP receptor discloses the role of the address domain of nociceptin/orphanin FQ.

Teodorico Tancredi1, Giacomo Carrà, Remo Guerrini, Marika Arduin, Girolamo Calò, Domenico Regoli, Severo Salvadori, Piero Andrea Temussi.   

Abstract

Nociceptin is a heptadecapeptide whose sequence is similar to that of Dynorphin A, sharing a message domain characterized by two glycines and two aromatic residues, and a highly basic C-terminal address domain but, in spite of these similarities, displays no opioid activity. Establishing the relative importance of the message and address domains of nociceptin has so far been hampered by its extreme conformational flexibility. Here we show that mutants of this peptide, designed to increase the helical content in the address domain, can be employed to explain the mode of interaction with the NOP receptor. Nociceptin analogues in which Ala residues are substituted with aminoisobutyric acid (Aib) show a substantial increment of activity in their interaction with the NOP receptor. The increment of biological activity was attributed to the well-documented ability of Aib to induce helicity. Here we have verified this working hypothesis by a conformational investigation extended to new analogues in which the role of Aib is taken up by Leu. The NMR conformational analysis confirms that all Ala/Aib peptides as well as [Leu(7,11)]-N/OFQ-amide and [Leu(11,15)]-N/OFQ-amide mutants (N/OFQ=nociceptin/orphanin FQ) have comparable helix content in helix-promoting media. We show that the helical address domain of nociceptin can place key basic residues at an optimal distance from complementary acidic groups of the EL(2) loop of the receptor. Our structural data are used to rationalize pharmacological data which show that although [Leu(11,15)]-N/OFQ-amide has an activity comparable to those of Ala/Aib peptides, [Leu(7,11)]-N/OFQ-amide is less active than N/OFQ-amide. We hypothesize that bulky residues cannot be hosted in or near the hinge region (Thr(5)-Gly(6)-Ala(7)) without severe steric clash with the receptor. This hypothesis is also consistent with previous data on this hinge region obtained by systematic substitution of Thr, Gly, and Ala with Pro.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15712334     DOI: 10.1002/chem.200401095

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  6 in total

Review 1.  UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.

Authors:  Girolamo Calo'; Anna Rizzi; Carlo Cifani; Maria Vittoria Micioni Di Bonaventura; Domenico Regoli; Maurizio Massi; Severo Salvadori; David G Lambert; Remo Guerrini
Journal:  CNS Neurosci Ther       Date:  2010-05-18       Impact factor: 5.243

Review 2.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

3.  Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic.

Authors:  Aaron A Thompson; Wei Liu; Eugene Chun; Vsevolod Katritch; Huixian Wu; Eyal Vardy; Xi-Ping Huang; Claudio Trapella; Remo Guerrini; Girolamo Calo; Bryan L Roth; Vadim Cherezov; Raymond C Stevens
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

4.  Structure- and conformation-activity studies of nociceptin/orphanin FQ receptor dimeric ligands.

Authors:  Salvatore Pacifico; Alfonso Carotenuto; Diego Brancaccio; Ettore Novellino; Erika Marzola; Federica Ferrari; Maria Camilla Cerlesi; Claudio Trapella; Delia Preti; Severo Salvadori; Girolamo Calò; Remo Guerrini
Journal:  Sci Rep       Date:  2017-04-06       Impact factor: 4.379

5.  Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1-13)-NH2.

Authors:  Salvatore Pacifico; Federica Ferrari; Valentina Albanese; Erika Marzola; Joaquim Azevedo Neto; Chiara Ruzza; Girolamo Calò; Delia Preti; Remo Guerrini
Journal:  J Med Chem       Date:  2020-09-24       Impact factor: 7.446

6.  In vitro pharmacological characterisation of a novel cyclic nociceptin/orphanin FQ analogue c[Cys(7,10)]N/OFQ(1-13)NH (2).

Authors:  M Kitayama; J McDonald; T A Barnes; G Calo'; R Guerrini; D J Rowbotham; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-06-28       Impact factor: 3.195

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.